
Feb 4 (Reuters) - Cumberland Pharmaceuticals Inc CPIX.O:
CUMBERLAND PHARMACEUTICALS ANNOUNCES BREAKTHROUGH RESULTS FROM THE PHASE 2 FIGHT DMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY HEART DISEASE
CUMBERLAND PHARMACEUTICALS INC - IFETROBAN WELL-TOLERATED WITH NO SERIOUS DRUG-RELATED EVENTS
Source text: ID:nPn9B7wCBa
Further company coverage: CPIX.O